Investors & Media

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

–         Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – –         Results demonstrate olezarsen may represent a novel treatment option for this rare,

Read more
You are now leaving https://www.ionispharma.com to visit